Evercore ISI analyst Gavin Clark-Gartner downgraded Foghorn Therapeutics (NASDAQ: FHTX) from Outperform to In Line with a price target of ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Downgrades